Skip to main content
. 2017 Mar 21;47(1):45–50. doi: 10.5624/isd.2017.47.1.45

Table 3. Prevalence of bisphosphonate-related osteonecrosis of the jaw according to drug type, duration of administration, and CTx level.

graphic file with name isd-47-45-i003.jpg

*Statistically significant difference at P<.05, BRONJ: bisphosphonate-related osteonecrosis of the jaw, CTx: C-terminal telopeptide, Alen: alendronate, Iban: iIbandronate, Rise: risedronate